Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Rift Valley fever virus glycoprotein Gc is a structural envelope glycoprotein encoded by the M segment of the RVFV genome[8][3][6]. Gc, together with Gn, is essential for virus assembly and mediates viral attachment and membrane fusion with the host cell, a process activated by low pH in endosomes following endocytosis[2][6][7]. Structural studies demonstrate that Gc is a class II viral fusion protein, sharing architecture with fusion proteins from flaviviruses and alphaviruses, and undergoes an acid-triggered conformational change critical for membrane fusion[2][5][7]. Gc is the principal effector of viral entry and a major target for neutralizing antibodies, making it a key focus for the development of vaccines and antiviral therapeutics[1][8]. Gc is glycosylated and forms heterodimers with Gn, contributing to the quaternary structure and antigenicity of the viral particle[1][3][5].
Inhibition of membrane fusion - Blockade of viral entry - Neutralization by antibodies
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Rift Valley fever virus glycoprotein Gc (Gc).